Stryker Corp is highlighted as a leading medical technology company, innovating in orthopedics, medsurg, and neurotechnology. The article emphasizes its strong market presence in the US, with a significant revenue base from US hospitals. Stryker's robust financial performance in Q1 2026, driven by its diversified product portfolio and strategic acquisitions, positions it well within the growing global medical devices market.

US Bancorp's shares dropped 3.2% to $52.74 on May 13, 2026, extending a 6.1% weekly decline despite the bank topping Q4 CY2025 earnings estimates with revenue of $7.37 billion and EPS of $1.26. The financial services company, a major US holding company operating in banking, investment, mortgage, trust, and payment services, saw its revenue increase by 5.1% year-over-year. Investors are watching for sustained growth in upcoming quarters amidst economic uncertainties.

Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (IDS) subsidiary. This new assay, alongside existing tests for free testosterone and sex hormone-binding globulin (SHBG), offers a fully integrated diagnostic approach for testosterone-related disorders on a single platform. This advancement aims to streamline workflow and centralize diagnostics for identifying suspected hypogonadism in men, replacing complex legacy methods.

SK Bioscience Co Ltd significantly expanded its partnership with Sanofi in December 2024 to develop and commercialize pneumococcal vaccines, strengthening its position in the global biotech and vaccine markets. This collaboration, along with strong Q1 2026 provisional results, highlights the company's growth potential and its relevance for US investors seeking exposure to international biotech innovations. SK Bioscience focuses on vaccine R&D and manufacturing, leveraging advanced platforms and strategic alliances to address global health needs.

This article provides market data for the Global X Defense Tech ETF (Derivatives) with the ticker SHLD. It lists current prices, 24-hour changes, highs, lows, and trading volumes from various exchanges, specifically mentioning OKX Futures and MEXC Futures. The content appears to be a snapshot from a cryptocurrency market data platform.

SIM Acquisition Corp. I (Nasdaq: SIMA, SIMAW) announced that its shareholders approved an extension to the business combination deadline until July 12, 2027, from the original July 11, 2026. This decision followed an extraordinary general meeting where a substantial 22,447,232 public shares were redeemed at approximately $10.79 per share, leaving only 552,768 public shares outstanding. The company also converted all 4,666,667 Class B Ordinary Shares into Class A Ordinary Shares, impacting ownership and potentially increasing share price volatility due to the reduced public float.

Bank of America Global Research initiated a Buy rating for Autodesk (US0527691069) on May 12, 2026, setting a $300 price target. This reflects confidence in Autodesk's design software platform, especially with increasing enterprise adoption of cloud and AI-driven tools. Despite recent stock volatility and broader market concerns, analysts see significant long-term potential for the company.

Ameritas Advisory Services LLC significantly increased its stake in Duke Energy Corporation (DUK) by 174.1% in the fourth quarter of 2025, bringing its total holdings to 15,727 shares valued at $1.84 million. This move comes as Duke Energy recently exceeded Q1 expectations with EPS of $1.93 and revenue of $9.18 billion, also announcing a quarterly dividend of $1.065 per share. Analysts have maintained a "Moderate Buy" consensus for DUK with an average price target of $140, despite some recent slight adjustments to price targets and insider selling by top executives.

Ameritas Advisory Services LLC significantly increased its stake in T-Mobile US, Inc. (TMUS) by 3,194.9% in the fourth quarter, holding 10,379 shares valued at $2.1 million. This comes as T-Mobile reported strong earnings, beating expectations with a 10.6% year-over-year revenue increase and declaring a $1.02 quarterly dividend. Analysts maintain a "Moderate Buy" rating for TMUS with an average price target of $260.48.

Ameritas Advisory Services LLC significantly increased its stake in The TJX Companies, Inc. by 584.7% in the fourth quarter, now holding 14,673 shares valued at approximately $2.25 million. This move follows TJX's strong quarterly results, including beating EPS estimates and an 8.5% revenue increase, and precedes a raised quarterly dividend to $0.48 per share. The company maintains a "Buy" consensus rating from analysts with an average price target of $167.55.